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STATISTICAL CONSIDERATIONS

Primary Objective
The primary endpoint of this study is the time to progression (TTP), starting at transplant, with progression defined in the protocol document, as follows: Progressive disease (for patients not in complete response) requires one or more of the following: • >25% increase in the level of the serum monoclonal paraprotein, which must also be an absolute increase of at least 0.5 g/dL and confirmed by at least one repeated investigation.
• >25% increase in the 24-hour urinary light chain excretion, which must also be an absolute increase of at least 200 mg/24-hour and confirmed by at least one repeated investigation.
• >25% increase in plasma cells in a bone marrow aspirate or trephine biopsy, which must also be an absolute increase of at least 10%.
• Definite increase in the size of existing bone lesions or soft tissue plasmacytomas.
• Development of new bone lesions or soft tissue plasmacytomas (development of a compression fracture does not exclude continued response).
• Development of hypercalcemia (corrected serum calcium > 11.5 mg/dL or 2.8 mmol/L) not attributable to any other cause in Section 11.2.5 of the protocol document, in MM patients. Time to progression will start at Day 0 of start of transplant. Any death will be considered as an event (i.e., will not be censored). We hypothesize that the treatment arm will be superior with respect to this endpoint.
Throughout these discussions, we assumed that the laws of the time-to-event in both arms are exponential. The hypothesis of interest may be canonically presented as testing H0: Δ=1 versus the general alternative H1: Δ >1, where Δ denotes the treatment to control hazard ratio. In particular, we hypothesize that the median TTP is Mc=2 years (24 months) for the control arm and Me=2.8 years (33.6 months) for the treatment arm. This corresponds to testing H0: Δ=1 versus the local alternative H1:Δ=1.4.
Given that the observed accrual pattern has differed considerably from that assumed in the original design, an amendment to the statistical considerations was necessitated so as to comply with the CTEP low accrual policy. Furthermore, the TTP distribution assumptions in this amendment and the targeted number of events (309) are identical to those of the original design. What is subject to amendment is only the assumed distribution of the administrative censoring mechanism. As such, amendment should have no effect on the risk to benefit ratio of the original design.
Secondary Objectives
The rates for the various types of responses pre-randomization, at 3 months and at 12 months will be estimated. The improvement in response (e.g., PR to CR) over the aforementioned time-points will be analyzed as well. The potential discrepancies between the TTP profiles for the CR and non-CR group on the study drug arm will be described. We expect little differences in patient responses by sex or race.
The marginal survival distributions for time to progression, overall survival and EFS are estimated using Kaplan-Meier estimators. 1 Time-to-event distributions between the two arms are compared using the log-rank test for univariable analysis and the Cox score test 2 for multivariable analysis adjusting for baseline patient characteristics. The corresponding effect size is quantified on the basis of the hazard ratio under the framework of a proportional hazard model. To estimate and compare cause-specific hazard (progression, death and second primary malignancy), marginal estimators of the corresponding cumulative incidence profiles 3 and the log-rank test proposed by Gray 4 are used. To test whether there is an interaction between a baseline co-variable and randomization arm, a two-way multiplicative Cox model is employed. A forest plot is used to provide a graphical presentation of the absolute and relative effect sizes. For this plot, the effect size is presented as the log hazard ratio (i.e., the regression coefficient from the Cox model). The radii of the circles are proportional the inverse of the square of the standard error. It is noted that all hazard ratios discussed in the text and illustrated in the forest plot have been quantified within the context of univariable Cox model without accounting for other additive or multiplicative effects. For all of time to event analyses, standard asymptotics is employed to characterize the sampling distributions for the statistics and estimators. As a descriptive analysis, the discrepancies between the response at time of randomisation profiles of the two arms were assessed using Fisher's exact test. 5 For the progressive disease events, patients for whom no event had been realized were censored at the last documented clinical assessment date at which they were found to be in remission. For the overall survival endpoint, patients who are alive are censored at the last date of follow-up. Some patients withdrew consent to further follow-up. For these patients, only follow-up information provided on or before the date of withdrawal of consent was used.
While the progressive disease and second primary malignancy events are subject to interval censoring, in the analyses, they have been right censored to the date of clinical assessment. The statistical analyses are carried out using the R statistical environment (version 3.3.2) along with the survival (version 2.39-5) and cmprsk (version 2.2-7) extension packages.
Randomisation/blinding:
The blinding table was generated by CALGB IS and was kept on a secure server. Only the study statisticians had access to the unblinding application. The Executive Officer authorized unblinding in case of an emergency. At that point either Vera Hars or a member of the IS department could unblind the treatment via an unblinding application. Vera Hars had access to the randomisation table and received notice about each randomisation which included the stratification factors of the newly randomised patient. As per CALGB guidelines regarding randomised double-blinded studies, study statisticians confirmed that the patient was assigned to the correct treatment (the next treatment of the current block of six treatments within his/her stratum) for the first 10-20 patients.
Interim analyses/stopping rules/DSMB monitoring: As per the protocol: A group sequential test design due to Emerson and Fleming 6 will be used to stop the trial early for superiority of the experimental drug. The study will also be monitored for futility. In particular, at each of the seven interim analyses the hypothesis that the hazard ratio is at least 1.4 will be tested at a fixed one-side significance level of 0.005. The upper boundary will be truncated by the 1-0.005 quantile of a standard normal distribution. For calculating the futility bound, we will assume that the standardized log-rank statistic, after the d-th event has occurred, is normally distributed with the unit variance and mean log [1.4] (d/4)0.5. Note that among other things, this assumption not only depends on asymptotic results but also on approximating the mean of the asymptotic distribution. For illustrative purposes, we provide the lower and the upper boundaries (in the so called normalized z-score scale) that would be used under the specific assumptions in the table below. We reiterate that these bounds are for illustrative purposes only as these calculations were based on various assumptions that were rarely realized in practice. This rather extensive monitoring plan has, as discussed in Freidlin et al. 7 , a negligible impact on the planned Type 1 and II error rates of this trial. Toxicity Stopping Rules: If > 20% of patients randomized to the CC-5013 arm permanently discontinue the drug due to drug-related toxicity within one year following randomization, the treatment will be considered overly toxic and consideration will be given to terminate the study.
Analysis
The study was monitored by the CALGB Data and Safety Monitoring Board (DSMB) on a semiannual basis in June and November of each year per CALGB policy. Per protocol, the first interim analysis was to be presented after at least 20% of the expected events had been realized. A group sequential design was employed to monitor time to progression for superiority. The bounds were truncated by the 1-0.005 quantile of a standard normal distribution. Time to progression was also to be monitored for futility at each interim analysis to test the specific hypothesis that the hazard ratio is at least 1.4 as a fixed one-sided level of 0.005. A randomized permuted block procedure using three stratification factors (β-2M elevation, prior thalidomide induction therapy and prior lenalidomide induction therapy) was employed.
The study was opened on 12/15/2004. Accrual to the study did not begin until 04/2005. Given that the observed accrual rate had differed considerably from that assumed in the original design, an amendment to the statistical considerations was necessitated so as to comply with an NCI CTEP policy regarding accrual. It is noted that the study team had not carried out any interim analyses when this amendment was drafted and consequently approved. Furthermore, the time to progression distribution assumptions in the amendment and the targeted number of events (309) were identical to those of the original design. Only the assumed distribution of the administrative censoring mechanism had been revised.
The DSMB reports, including analysis results, summaries and recommendations, were drafted and presented by the statistical team. The clinical team members, including the study chair and data coordinators, were blinded with respect to these analyses and results. The PI and the treating team had no access to the DSMB. The DSMB met in closed sessions and the members were required to destroy the DSBM reports after their meetings. The first time the PI had access to the data was at the time of study unblinding.
June 2009
Interim analysis: According to the protocol, the first interim analysis for efficacy was scheduled to be carried out for presentation at the first DSMB meeting after at least 20% of the 309 expected events (progressions or deaths) had occurred. This corresponds to at least 61 events. Out of the 375 patients randomized to the study, 74 have realized an event. This report provides a summary of the first interim analysis for this study. There have been 18 deaths among the randomized patients all of whom have experienced a progression event on or before time of death. The median follow-up time for TTP is 360 days (95% CI=347,369). Among the 188 patients randomized to the CC-5013 arm, 24 experienced a progression event. This compares to 50 events among the 187 patients randomized to the placebo arm. The observed value of the standardized log-rank statistic for testing for the association between TTP and treatment is 3.94. This exceeds the first bound of the superiority boundary which is 2.576 and corresponds to an asymptotic P-value of less than 0.0001. Under a log-linear proportional hazards framework the estimated hazard ratio is 0.39 (95% CI=0.24,0.63). The data suggests that there is ample statistical evidence that CC-5013 based maintenance therapy following ASCT reduces time to progression.
Sep 2009 Interim analysis:
According to the results from the first interim analysis presented during the June 2009 DSMB meeting, there was strong statistical evidence to support the hypothesis that adding CC-5013 based maintenance therapy following ASCT prolongs time to progression for multiple myeloma patients. The results from this second interim analysis reaffirm those findings. The results from this second interim analysis are based on more mature outcome data (28% rather than 21% of the 309 events targeted in the statistical design) and a considerably more up to date database. The results are rather striking and per the decision rule of the study design warrant consideration for release of the study data to the study team. There is not enough evidence to support the hypothesis that CC-5013 maintenance therapy improves overall survival in this patient population (two-sided P-value <0.2). Although there is an apparent, albeit weak, observed trend in favor of the CC-5013 maintenance arm with respect to survival.
Based on the strong evidence in support of the primary objective hypothesis of this study, namely that addition of CC-5013 based maintenance therapy following ASCT prolongs time to progression in the protocol population, the primary hypothesis of the study, we recommend that the data for CALGB 100104 are released to the study team. We emphasize that this recommendation is solely based on the observed prolongation in time to progression in support of the primary hypothesis of the protocol as it is too early to conclude anything about overall survival. If this recommendation is approved by the DSMB, we will conduct one additional analysis after completing the official CALGB procedures for study database finalization. If our recommendation is not approved, we will present a third interim analysis for efficacy at the November 2009 DSMB meeting as mandated by the protocol.
Addendum to CALGB 100104 Interim Analysis Report: This report is submitted as an addendum to the second interim analysis of efficacy report for CALGB 100104 produced on 09/14/2009. The latter was produced at the request of the DSMB as an update to the June 2009 DSMB report. In this addendum, we report the results from a limited sensitivity analysis.
The analysis data set for the updated analysis is comprised of 418 patients randomized on or before 07/31/2009. Among these there are 16 cases with missing ASCT dates. More specifically, twelve out of the 208 patients randomized to the placebo arm and four out of the 210 patients randomized to the maintenance therapy arm are missing ASCT dates. In the updated analysis, these cases are censored at time zero which effectively excludes them from the calculation of the test statistic.
It is reasonable assume that the TTP profile of the maintenance therapy will not be any worse than that of the placebo arm. It is noted that these 16 patients were randomized in the period starting 05-27-09 and ending 07-30-09. As these are all recent cases, it is also reasonable to assume that the missingness pattern is non-informative. In other words, it is the case of the respective institutions not having submitted the paperwork.
Under this set of assumptions, we will simulate the 16 missing cases from the placebo arm. More specifically, for each simulation replicate, we draw 16 pairs (observed time and censoring indicator) at random with replacement from the 196 (=208 -12) pairs on the placebo arm with complete ASCT date information.
The histogram of B=10000 bootstrap replicates is shown below. The median of these replicates is 3.89 while the first and second quartiles are 3.77 and 4.02 respectively. The realized value of the test statistic (Z=3.85 is marked by a vertical line on the histogram. According to the statistical design, the upper boundary for the second interim analysis is 2.57 (the -0.005 quantile of a standard normal law). It is noted that none of the bootstrap replicates are below this threshold.
Histogram of B=10000 bootstrap replicates of the standardized log-rank statistic obtained by imputing the missing cases from the placebo arm
This has been an attempt to study the potential impact of the 16 missing cases under a set of assumptions. The purpose of this analysis is not to approximate the null sampling distribution of the test statistic. Rather, this has been an attempt to study the potential impact of the 16 missing cases by assuming that the missing cases are identically distributed according to the distribution on the placebo arm. Based on the result of the actual analysis, we recommended that the study data be released to the study team. The results from this sensitivity analysis does not suggest that we would reach a different conclusion if these 16 missing cases happen to be all distributed to the placebo arm. It is noted that this approach has several caveats. Most notably, it neither takes into account the sequential nature of the statistical design nor does take into account stratification factors. . This compares to 58 events among the 208 patients randomized to the placebo arm. The observed value of the standardized log-rank statistic for testing for the association between TTP and treatment is 3.85. This exceeds the second bound of the superiority boundary which is 2.576 and corresponds to an asymptotic one-sided Pvalue of less than 0.0001. Under a proportional hazards framework the estimated hazard ratio is 0.42 (95% CI=0.27,0.66). The data suggests that there is ample statistical evidence that CC-5013 based maintenance therapy following ASCT prolongs time to progression. There is not enough statistical evidence to conclude that the maintenance therapy improves overall survival (two-sided P-value <0.2). It is noted that these estimates, test statistics and P-values have not been adjusted to take into account that one interim analysis has been carried out. The upper boundary is adjusted for multiple testing. The adjusted P-value is in the interval (0.0001,0.005).
Eligibility Criteria:
Active Initial Required Laboratory Values: ANC > 1000/µL, platelets > 100,000/µL, creatinine clearance > 40 cc/min, creatinine < 2 mg/dL, total bilirubin < 2 mg/dL, AST/alkaline phosphatase < 3 x upper limits of normal, and negative urine-HCG or serum HCG if patient of childbearing potential. Creatinine clearance to be calculated by method of Cockcroft-Gault or after 24-hour urine collection.
Myeloma Monitoring during Maintenance Therapy:
Myeloma laboratory studies were to be done every three months for four years then every six months thereafter. Skeletal surveys were to be done annually for five years. Bone marrow aspirate/biopsy was to be done at 3 and 12 months after Day 0 of ASCT and then yearly until five years post-ASCT and at time of progression.
Dose Modifications:
Patients were scheduled to be re-staged between day 90-100 post-autologous hematopoietic cell transplant (AHCT) and those with SD or better were scheduled to start therapy between day 100 to 120 post-AHCT. All patients started on 2 pills (10 mg of lenalidomide) daily. Hematologic dose modifications were as follows:
Months 1-3: If on 2 capsules per day, the absolute neutrophil count (ANC) is <500/μL or the platelet count is <30,000/μL, then the study drug will be held for 8 weeks. Study drug may be re-instituted at 1 capsule per day if ANC is ≥500/μL or the platelet count is ≥30,000/μL. If, however, after an 8 week treatment delay, the ANC remains <500/μL or the platelet count <30,000/μL, the patient will be removed from protocol therapy. If on 1 capsule per day, the ANC is <500/μL or the platelet count is <30,000/μL, then the study drug will be held for 8 weeks. If ANC ≥500/μL or the platelet count is ≥30,000/μL, then study drug may be re-instituted at 1 capsule per day for 21 of 28 days. If, however, after an 8 week treatment delay, the ANC remains <500/μL or the platelet count <30,000/μL, the patient will be removed from protocol therapy. If on 1 capsule per day for 21 of 28 days, the ANC is <500/μL or the platelet count is <30,000/μL, then the patient will be removed from protocol therapy.
Beyond Month 3: If on 3 capsules per day, the ANC is <500/μL or the platelet count is <30,000/μL, then the study drug will be held for 8 weeks. Study drug may be re-instituted at 2 capsules per day if ANC is ≥500/μL or platelet count is ≥30,000/μL. If, however, after an 8 week treatment delay, the ANC remains <500/μL or platelet count <30,000/μL, the patient will be removed from protocol therapy. If on 2 capsules per day, the ANC is <500/μL or the platelet count is <30,000/μL, then the study drug will be held for 8 weeks. If ANC is ≥500/μL or the platelet count is ≥30,000/μL, then study drug may be reinstituted at 1 capsule per day. If, however, after an 8 week treatment delay, the ANC remains <500/μL or the platelet count <30,000/μL, the patient will be removed from protocol therapy. If on 1 capsule per day, the ANC is <500/μL or the platelet count is <30,000/μL, then the study drug will be held for 8 weeks. If ANC ≥500/μL or the platelet count is ≥30,000/μL, then study drug may be re-instituted at 1 capsule per day for 21 of 28 days. If, however, after an 8 week treatment delay, the ANC remains <500/μL or the platelet count <30,000/μL, the patient will be removed from protocol therapy. If on 1 capsule per day for 21 of 28 days, the ANC is <500/μL or the platelet count is <30,000/μL, then the patient will be removed from protocol therapy.
Dose Escalation Beyond Month 3:
If a dose reduction has occurred and ANC ≥1000/μL and platelet count is ≥75,000/μL, the study drug dose may be re-escalated by one level (i.e., one capsule every day to two capsules every day, etc.). Hematologic parameters must remain at these threshold values for one month before another dose escalation may occur. Maximum study drug dose will be 3 capsules per day. If for any reason, a patient is not able to be dose escalated, dose escalation should be attempted by the time of the next re-staging. If at next restaging, the patient has not recurred or progressed, and the patient is not able to be dose escalated, patient may continue on treatment at current dose level. If for any reason the drug is held for a non-grade 3 hematologic toxicity, the drug will be held until the toxicity resolves and the drug started at one dose level lower. The drug should be re-escalated to the original dose within 4 weeks. The drug should be escalated as per the criteria listed above. A) The CIR of PD or death from any cause is higher with placebo compared to lenalidomide (p<0·0001). The CIR of developing a SPM is higher with lenalidomide compared with placebo (p=0·0002). B) The CIR of death from any cause is higher with placebo compared with lenalidomide (p<0·0001). C) The CIR of death from myeloma is higher with placebo than with lenalidomide (p<0·0001) while the CIR of death from SPM is higher with lenalidomide than placebo (p=0·033).
Figure S10: Cumulative incidence risk (CIR) of progressive disease, death, and second primary malignancies (SPMs) comparing patients in the lenalidomide arm to those patients in the placebo arm who crossed over to receive lenalidomide. A) There is no difference in the CIR of progressive disease or death from any cause between the lenalidomide and crossover groups (p=0·85). There is no difference in the CIR of developing a SPM between the lenalidomide and crossover groups (p=0·83). B) There is no difference in the CIR of death from any cause between the lenalidomide and crossover groups (p=0·54). C) There are no differences in the CIR of death from myeloma (p=0·56) or death from SPM (p=0·30) between the lenalidomide and crossover groups. (5) 55 (24) 163 (71) 11 (5) 105 (23) 333 (72) 22 ( (48) 13 (6) 28 (12) 59 (26) 129 (56) 13 (6) 63 (14) 130 (28) (6) 2 (1) 0 13 (6) 4 (2) 35 (15) 76 (33) 31 (14) 20 (9) 13 (6) 1 (<1) 1 (<1)
12 (5) 10 (4) 41 (18) 146 (32) 74 (16) 41 (9) 26 (6) 3 (1) 1 (<1) 24 (5) 14 ( 1 This study's off-treatment form did not require the sites to specify which adverse event led to treatment discontinuation, although in some cases this information was provided as a comment on the form. For those patients for whom such comments were not provided, chart review was performed by S.A.H. to adjudicate the adverse event/s associated with treatment discontinuation. This review involved the utilization of study adverse event reporting forms from the time period of treatment discontinuation, AdEERs reports, or primary source documents (i.e., clinic notes). *This patient was subsequently suspected to have amyotrophic lateral sclerosis **A few patients had two adverse events which contributed to study discontinuation. Abbreviations: Bor, bortezomib; Car, carfilzomib; Cy, cyclophosphamide; Dara, daratumumab; Dex, dexamethasone; Dox; liposomal doxorubicin; hyperCVAD, hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone; IMiD, immunomodulatory; Len, lenalidomide; Pom, pomalidomide, Thal, thalidomide Table S11 . Second primary malignancies in patients who were enrolled but never randomized.
Hematological (n) Solid tumor (n) Noninvasive skin cancer (n) MDS (1) Melanoma (2) Adenocarcinoma of unknown primary (1) Bladder (1) Breast (1) Cholangiocarcinoma (1) Intraductal papillary mucinous cystic neoplasm of the pancreas (1) BCC (1) SCC (1) 
